Global Radiotherapy Market by Products, Technology & Applications Till 2016

“Global Radiotherapy Market by Products, Technology & Applications Till 2016 - Cyberknife, Gammaknife, Linac, Tomotherapy, Cyclotron, Synchrotron, Radionuclides, Iodine-131, IMRT, IGRT, Volumetric Modulated Arc Therapy & Stereotactic Radiosurgery”

Radiotherapy refers to the therapeutic procedures using high energy electromagnetic waves or radioactive particulates to thwart abnormal cell growths within our body system and repair different physiological abnormalities. This report analyzes the market potential for devices used in radiotherapies for different body systems. This device market encompasses devices for external beam radiation therapy (CyberKnife, Gamma Knife, electron emitting high energy linear accelerators, proton therapy machines etc), brachytherapy (seeds, applicators-afterloaders, and electronic brachytherapy) and systemic radiation therapy (Iodine-131, Samarium-153, Rhenium-186, Erbium-169, etc.).

The global radiotherapy devices market, consisting of devices used in both systemic and blood-borne oncology treatment procedures, was valued at $4.4 billion in 2011 and is expected to reach $5.8 billion by 2016, at a CAGR of 5.3% from 2011 to 2016. External beam therapy devices contribute the maximum share (81.5%) to the global radiotherapy devices market, followed by internal radiotherapy devices (9.6%) and systemic radiotherapy devices (8.9%).

The major driving factor for these markets involves reimbursement support to the radiotherapy procedures in the developed countries over conventional therapeutic procedures. As the incidence cases of cancer diseases continue to rise in the coming years, along with increasing trends in accurate diagnosis and precise treatment planning system, the radiotherapy devices market for treating these diseases would show significant growth in the forecast period.

The external beam radiation therapy in radio-oncology represents the largest segment of the market. In the global radiotherapy market, the linear accelerator devices market contributed the largest share (65%) of the total market with $2.8 billion in 2011 and is expected to reach $3.7 billion by 2016. The key driving factor for this market would be the increased usage of these devices due to significant technological revolution and its capability to provide better and precise treatment services.

North America is the biggest market for vascular interventional devices, followed by Europe. However, Asian countries represent the most promising and fastest growing markets as low procedural and infrastructural costs have led to an increased drive of patients from developed regions towards Asian countries such as India and China.

Major players in the market include Varian Medical System (U.S.), Elekta AB (Sweden) and Accuray (U.S.), IBA Group (Belgium), Eckert & Ziegler BEBIG (Belgium), iCAD, Inc. (U.S.), GE Healthcare (U.K.), Covidien, PLC (Ireland), C.R. Bard, Inc. (U.S.), Nordion, Inc. (Canada), Theragenics Corporation (U.S.), Oncura, Inc. (U.S.) among others.

TABLE OF CONTENTS 
 
1 INTRODUCTION 
  1.1 KEY TAKE-AWAYS 
  1.2 REPORT DESCRIPTION 
  1.3 MARKETS COVERED 
  1.4 STAKEHOLDERS 
  1.5 RESEARCH METHODOLOGY 
      1.5.1 MARKET SIZE 
      1.5.2 MARKET SHARE 
      1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 
      1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 
      1.5.5 ASSUMPTIONS 
 
2 EXECUTIVE SUMMARY 
 
3 MARKET OVERVIEW 
  3.1 INTRODUCTION 
  3.2 MARKET SEGMENTATION 
  3.3 MARKET DYNAMICS 
      3.3.1 DRIVERS 
            3.3.1.1 Rapidly changing cancer treatment technology forces continual innovation 
            3.3.1.2 Healthy reimbursement plans are facilitating the growth in developed countries 
            3.3.1.3 Untapped markets in the emerging countries are pushing up market growth 
            3.3.1.4 Cost-effective and precise treatment procedure is alluring more market penetration 
            3.3.1.5 Growing number of cancer patients is pulling up market demand 
      3.3.2 RESTRAINTS 
            3.3.2.1 Alternative treatment procedure hinders the radiotherapy growth 
            3.3.2.2 Lack of adequate infrastructure & healthcare expenditure restrict the market growth 
            3.3.2.3 Lack of adequate skills & training is limiting the radiotherapy growth 
      3.3.3 THREATS & OPPORTUNITIES 
  3.4 TRENDS 
  3.5 MARKET SHARE ANALYSIS OF MAJOR PLAYERS 
 
4 GLOBAL RADIOTHERAPY DEVICES MARKET, BY PRODUCTS (VALUE & VOLUME ANALYSIS) 
  4.1 INTRODUCTION 
  4.2 EXTERNAL BEAM RADIATION THERAPY 
      4.2.1 INTRODUCTION 
      4.2.2 COMPACT ADVANCED RADIOTHERAPY SYSTEMS 
            4.2.2.1 CyberKnife 
            4.2.2.2 Gamma Knife 
            4.2.2.3 TomoTherapy 
      4.2.3 PROTON THERAPY SYSTEMS 
            4.2.3.1 Cyclotron 
            4.2.3.2 Synchrotron 
      4.2.4 ELECTRON EMITTING HIGH ENERGY LINEAR ACCELERATORS (LINAC) 
  4.3 INTERNAL RADIATION THERAPY/BRACHYTHERAPY 
      4.3.1 SEEDS 
      4.3.2 APPLICATORS & AFTERLOADERS 
      4.3.3 ELECTRONIC BRACHYTHERAPY 
  4.4 SYSTEMIC RADIATION THERAPY 
      4.4.1 INTRODUCTION 
      4.4.2 IOBENGUANE (I-131) 
      4.4.3 RHENIUM (RE-186) 
      4.4.4 SAMARIUM (SM-153) 
      4.4.5 ERBIUM (ER-169) 
      4.4.6 YTTRIUM-90 (Y-90) 
 
5 GLOBAL RADIOTHERAPY DEVICES MARKET, BY APPLICATIONS (VALUE ANALYSIS) 
  5.1 INTRODUCTION 
  5.2 GLOBAL EXTERNAL BEAM RADIATION THERAPY 
      5.2.1 PROSTATE CANCER 
      5.2.2 BREAST CANCER 
      5.2.3 LUNG CANCER 
      5.2.4 HEAD & NECK CANCER 
      5.2.5 COLORECTAL CANCER 
      5.2.6 SPINE CANCER 
      5.2.7 NEUROSURGERY & BRAIN CANCER 
  5.3 GLOBAL INTERNAL RADIATION THERAPY 
      5.3.1 PROSTATE CANCER 
      5.3.2 GYNECOLOGICAL CANCER 
      5.3.3 BREAST CANCER 
      5.3.4 CERVICAL CANCER 
      5.3.5 PENILE CANCER 
      5.3.6 LUNG CANCER 
      5.3.7 HEAD & NECK CANCER 
      5.3.8 ESOPHAGEAL CANCER 
  5.4 GLOBAL SYSTEMIC RADIATION THERAPY 
 
6 GLOBAL RADIOTHERAPY DEVICES MARKET, BY TECHNOLOGY (VALUE ANALYSIS) 
  6.1 INTRODUCTION 
  6.2 EXTERNAL BEAM RADIATION THERAPY 
      6.2.1 INTENSITY MODULATED RADIATION THERAPY (IMRT) 
      6.2.2 IMAGE GUIDED RADIO THERAPY (IGRT) 
      6.2.3 TOMOTHERAPY 
      6.2.4 STEREOTACTIC TECHNOLOGY 
      6.2.5 3-D CONFORMAL RADIOTHERAPY 
      6.2.6 PROTON BEAM THERAPY 
      6.2.7 VOLUMETRIC MODULATED ARC THERAPY 
      6.2.8 ADAPTIVE RADIATION THERAPY 
  6.3 INTERNAL BEAM RADIOTHERAPY 
      6.3.1 LOW DOSE RATE 
      6.3.2 HIGH DOSE RATE 
  6.4 SYSTEMIC RADIATION THERAPY 
      6.4.1 INTRODUCTION 
      6.4.2 ROUTE OF ADMINISTRATION 
            6.4.2.1 Intravenous administration 
            6.4.2.2 Oral administration 
 
7 GEOGRAPHIC ANALYSIS 
  7.1 INTRODUCTION 
  7.2 NORTH AMERICA 
  7.3 EUROPE 
  7.4 ASIA 
  7.5 ROW 
 
8 COMPETITIVE LANDSCAPE 
  8.1 INTRODUCTION 
  8.2 MERGERS & ACQUISITIONS 
  8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 
  8.4 NEW PRODUCTS LAUNCH 
  8.5 APPROVALS 
  8.6 EXPANSIONS 
  8.7 OTHER DEVELOPMENTS 
 
9 COMPANY PROFILE 
  9.1 ACCURAY, INC. 
      9.1.1 OVERVIEW 
      9.1.2 FINANCIALS 
      9.1.3 PRODUCTS & SERVICES 
      9.1.4 STRATEGY 
      9.1.5 DEVELOPMENTS 
  9.2 ANGIODYNAMICS, INC. 
      9.2.1 OVERVIEW 
      9.2.2 FINANCIALS 
      9.2.3 PRODUCTS & SERVICES 
      9.2.4 STRATEGY 
      9.2.5 DEVELOPMENTS 
  9.3 AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION (ANSTO) 
      9.3.1 OVERVIEW 
      9.3.2 FINANCIALS 
      9.3.3 PRODUCTS & SERVICES 
      9.3.4 STRATEGY 
      9.3.5 DEVELOPMENTS 
  9.4 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 
      9.4.1 OVERVIEW 
      9.4.2 PRODUCTS & SERVICES 
      9.4.3 STRATEGY 
  9.5 BOSTON SCIENTIFIC CORPORATION 
      9.5.1 OVERVIEW 
      9.5.2 FINANCIALS 
      9.5.3 PRODUCTS & SERVICES 
      9.5.4 STRATEGY 
      9.5.5 DEVELOPMENTS 
  9.6 C. R. BARD, INC. 
      9.6.1 OVERVIEW 
      9.6.2 FINANCIALS 
      9.6.3 PRODUCTS & SERVICES 
      9.6.4 STRATEGY 
  9.7 CARDINAL HEALTH, INC. 
      9.7.1 OVERVIEW 
      9.7.2 FINANCIALS 
      9.7.3 PRODUCTS & SERVICES 
      9.7.4 STRATEGY 
      9.7.5 DEVELOPMENTS 
  9.8 CARL ZEISS AG 
      9.8.1 OVERVIEW 
      9.8.2 FINANCIALS 
      9.8.3 PRODUCTS & SERVICES 
      9.8.4 STRATEGY 
      9.8.5 DEVELOPMENTS 
  9.9 COVIDIEN, PLC 
      9.9.1 OVERVIEW 
      9.9.2 FINANCIALS 
      9.9.3 PRODUCTS & SERVICES 
      9.9.4 STRATEGY 
      9.9.5 DEVELOPMENTS 
  9.10 ECKERT & ZIEGLER BEBIG S.A. 
      9.10.1 OVERVIEW 
      9.10.2 FINANCIALS 
      9.10.3 PRODUCTS & SERVICES 
      9.10.4 STRATEGY 
      9.10.5 DEVELOPMENTS 
  9.11 ECZACIBAͺI -MONROL 
      9.11.1 OVERVIEW 
      9.11.2 FINANCIALS 
      9.11.3 PRODUCTS & SERVICES 
      9.11.4 STRATEGY 
      9.11.5 DEVELOPMENTS 
  9.12 ELEKTA AB 
      9.12.1 OVERVIEW 
      9.12.2 FINANCIALS 
      9.12.3 PRODUCTS & SERVICES 
      9.12.4 STRATEGY 
      9.12.5 DEVELOPMENTS 
  9.13 GE HEALTHCARE 
      9.13.1 OVERVIEW 
      9.13.2 FINANCIALS 
      9.13.3 PRODUCTS & SERVICES 
      9.13.4 STRATEGY 
      9.13.5 DEVELOPMENTS 
  9.14 IBA GROUP 
      9.14.1 OVERVIEW 
      9.14.2 FINANCIALS 
      9.14.3 PRODUCTS & SERVICES 
      9.14.4 STRATEGY 
      9.14.5 DEVELOPMENTS 
  9.15 ICAD, INC. 
      9.15.1 OVERVIEW 
      9.15.2 FINANCIALS 
      9.15.3 PRODUCTS & SERVICES 
      9.15.4 STRATEGY 
      9.15.5 DEVELOPMENTS 
  9.16 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE (POLATOM) 
      9.16.1 OVERVIEW 
      9.16.2 PRODUCTS & SERVICES 
      9.16.3 STRATEGY 
      9.16.4 DEVELOPMENTS 
  9.17 INSTITUTE OF ISOTOPES CO. LTD. 
      9.17.1 OVERVIEW 
      9.17.2 PRODUCTS & SERVICES 
      9.17.3 STRATEGY 
  9.18 ISORAY MEDICAL, INC. 
      9.18.1 OVERVIEW 
      9.18.2 FINANCIALS 
      9.18.3 PRODUCTS & SERVICES 
      9.18.4 STRATEGY 
      9.18.5 DEVELOPMENTS 
  9.19 NORDION, INC 
      9.19.1 OVERVIEW 
      9.19.2 FINANCIALS 
      9.19.3 PRODUCTS & SERVICES 
      9.19.4 STRATEGY 
      9.19.5 DEVELOPMENTS 
  9.20 PROTOM INTERNATIONAL, INC. 
      9.20.1 OVERVIEW 
      9.20.2 FINANCIALS 
      9.20.3 PRODUCTS & SERVICES 
      9.20.4 STRATEGY 
      9.20.5 DEVELOPMENTS 
  9.21 SIEMENS HEALTHCARE 
      9.21.1 OVERVIEW 
      9.21.2 FINANCIALS 
      9.21.3 PRODUCTS & SERVICES 
      9.21.4 STRATEGY 
      9.21.5 DEVELOPMENTS 
  9.22 THERAGENICS CORPORATION 
      9.22.1 OVERVIEW 
      9.22.2 FINANCIALS 
      9.22.3 PRODUCTS & SERVICES 
      9.22.4 STRATEGY 
      9.22.5 DEVELOPMENTS 
  9.23 VARIAN MEDICAL SYSTEMS, INC. 
      9.23.1 OVERVIEW 
      9.23.2 FINANCIALS 
      9.23.3 PRODUCTS & SERVICES 
      9.23.4 STRATEGY 
      9.23.5 DEVELOPMENTS 
 
 
LIST OF TABLES 
 
TABLE 1 GLOBAL RADIOTHERAPY DEVICES MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 2 RADIOTHERAPY DEVICES MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 3 GLOBAL EXTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 4 EXTERNAL BEAM THERAPY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 5 GLOBAL COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 6 CYBERKNIFE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 7 CYBERKNIFE SYSTEMS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 8 COMPARISON BETWEEN CYBERKNIFE, GAMMA KNIFE & OTHER LINIAC SYSTEMS 
TABLE 9 GAMMA KNIFE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 10 GAMMA KNIFE SYSTEMS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 11 TOMOTHERAPY SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 12 TOMOTHERAPY SYSTEMS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 13 GLOBAL PROTON THERAPY SYSTEMS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 14 PROTON THERAPY SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 15 ELECTRON EMITTING HIGH ENERGY LINEAR ACCELERATORS (LINAC) SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 16 ELECTRON EMITTING HIGH ENERGY LINEAR ACCELERATORS (LINAC) SYSTEMS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (NO. OF UNITS) 
TABLE 17 GLOBAL INTERNAL BEAM/BRACHYTHERAPY MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 18 INTERNAL BEAM/BRACHYTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 19 GLOBAL BRACHYTHERAPY SEEDS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 20 BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 21 CESIUM-131 BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 22 IODINE-125 BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 23 PALLADIUM-103 BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 24 IRIDIUM-192 BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 25 OTHER BRACHYTHERAPY SEEDS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 26 GLOBAL BRACHYTHERAPY SEEDS MARKET VOLUME, BY PRODUCTS, 2009 – 2016 (THOUSAND UNITS) 
TABLE 27 BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 28 CESIUM-131 BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 29 IODINE-125 BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 30 PALLADIUM-103 BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 31 IRIDIUM-192 BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 32 OTHER BRACHYTHERAPY SEEDS MARKET VOLUME, BY GEOGRAPHY, 2009 – 2016 (THOUSAND UNITS) 
TABLE 33 APPLICATORS & AFTERLOADERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 34 GLOBAL SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 35 SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 36 IODINE-131 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 37 RHENIUM-186 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 38 SAMARIUM-153 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 39 ERBIUM-169 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 40 YTTRIUM-90 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 41 OTHER RADIOISOTOPES MARKET REVENUE, BY GEOGRAPHY, 2009 – 2016 ($MILLION) 
TABLE 42 GLOBAL EXTERNAL BEAM THERAPY MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION) 
TABLE 43 GLOBAL INTERNAL BEAM THERAPY MARKET REVENUE, BY APPLICATIONS, 2009 – 2016 ($MILLION) 
TABLE 44 GLOBAL EXTERNAL BEAM THERAPY MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION) 
TABLE 45 COMPARATIVE BETWEEN TOMOTHERAPY & CONVENTIONAL TREATMENT 
TABLE 46 GLOBAL INTERNAL BEAM THERAPY MARKET REVENUE, BY TECHNOLOGY, 2009 – 2016 ($MILLION) 
TABLE 47 NORTH AMERICA: RADIOTHERAPY DEVICES MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 48 NORTH AMERICA: EXTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 49 NORTH AMERICA: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 50 NORTH AMERICA: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET VOLUME, BY SEGMENTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 51 NORTH AMERICA: INTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 52 NORTH AMERICA: SEEDS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 53 NORTH AMERICA: SEEDS MARKET VOLUME, BY PRODUCTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 54 NORTH AMERICA: SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 55 EUROPE: RADIOTHERAPY DEVICES MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 56 EUROPE: EXTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 57 EUROPE: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 58 EUROPE: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET VOLUME, BY SEGMENTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 59 EUROPE: INTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 60 EUROPE: SEEDS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 61 EUROPE: SEEDS MARKET VOLUME, BY PRODUCTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 62 EUROPE: SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 63 ASIA: RADIOTHERAPY DEVICES MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 64 ASIA: EXTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 65 ASIA: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 66 ASIA: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET VOLUME, BY SEGMENTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 67 ASIA: INTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 68 ASIA: SEEDS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 69 ASIA: SEEDS MARKET VOLUME, BY PRODUCTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 70 ASIA: SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 71 ROW: RADIOTHERAPY DEVICES MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 72 ROW: EXTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 73 ROW: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 74 ROW: COMPACT ADVANCED RADIOTHERAPY SYSTEMS MARKET VOLUME, BY SEGMENTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 75 ROW: INTERNAL BEAM THERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
TABLE 76 ROW: SEEDS MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 77 ROW: SEEDS MARKET VOLUME, BY PRODUCTS, 2009 – 2016 (NO. OF UNITS) 
TABLE 78 ROW: SYSTEMIC RADIATION THERAPY MARKET REVENUE, BY PRODUCTS, 2009 – 2016 ($MILLION) 
TABLE 79 MERGERS & ACQUISITIONS, 2009 – 2012 
TABLE 80 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2009 – 2012 
TABLE 81 NEW PRODUCTS LAUNCH, 2009 – 2012 
TABLE 82 APPROVALS, 2009 – 2012 
TABLE 83 EXPANSIONS, 2009 –2012 
TABLE 84 OTHER DEVELOPMENTS, 2009 – 2012 
TABLE 85 ACCURAY, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 86 ACCURAY, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 87 ACCURAY, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 88 ANGIODYNAMICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 201 ($MILLION) 
TABLE 89 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 90 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 91 ANSTO: TOTAL REVENUE OF RADIOISOTOPES, 2009 - 2011 ($MILLION) 
TABLE 92 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 
TABLE 93 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 94 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 95 C. R. BARD, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 96 C. R. BARD, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 97 C. R. BARD, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 (MILLION) 
TABLE 98 CARDINAL HEALTH, INC.: TOTAL REVENUE , 2009 - 2011 ($MILLION) 
TABLE 99 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 100 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 101 CARL ZEISS AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 102 CARL ZEISS AG: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 103 CARL ZEISS AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 104 COVIDIEN, PLC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 105 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 106 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE, 2009 – 2011 ($MILLION) 
TABLE 107 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 108 ECKERT & ZIEGLER BEBIG S.A.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 
TABLE 109 ECKERT & ZIEGLER BEBIG S.A.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 110 ELEKTA AB: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 111 ELEKTA AB: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 112 ELEKTA AB: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 113 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 114 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 115 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 
TABLE 116 IBA GROUP: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 
TABLE 117 IBA GROUP: TOTAL MARKET REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 118 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 119 ICAD, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 120 ICAD INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($ MILLION) 
TABLE 121 ISORAY MEDICAL, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011($MILLION) 
TABLE 122 NORDION: MARKET REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 
TABLE 123 NORDION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 124 NORDION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 125 SIEMENS AG: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 126 SIEMENS AG: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION) 
TABLE 127 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 128 THERAGENICS CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION) 
TABLE 129 THERAGENICS CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 130 THERAGENICS CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 131 VARIAN MEDICAL SYSTEMS, INC.: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 
TABLE 132 VARIAN MEDICAL SYSTEMS, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 133 VARIAN MEDICAL SYSTEMS, INC.: ONCOLOGY SYSTEM & X-RAY PRODUCTS, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
 
 
LIST OF FIGURES  
 
FIGURE 1 TRENDS IN RADIOTHERAPY MARKET REVENUE, BY SEGMENTS, 2009 – 2016 ($MILLION) 
FIGURE 2 RADIOTHERAPY MARKET REVENUE, BY GEOGRAPHY, 2011 
FIGURE 3 GLOBAL RADIOTHERAPY DEVICES MARKET SEGMENTATION 
FIGURE 4 MARKET DYNAMICS 
FIGURE 5 GLOBAL RADIOTHERAPY MARKET SHARE, BY PLAYERS, 2011 
FIGURE 6 GLOBAL EXTERNAL BEAM RADIATION THERAPY MARKET SHARE, BY PLAYERS, 2011 
FIGURE 7 INTERNAL BEAM RADIOTHERAPY MARKET SHARE, BY PLAYERS, 2011 
FIGURE 8 SYSTEMIC RADIATION THERAPY MARKET SHARE, BY PLAYERS, 2011 
FIGURE 9 VARIOUS STEPS IN EXTERNAL BEAM RADIATION TREATMENT PROCESS 
FIGURE 10 BUBBLE CHART: EXTERNAL BEAM RADIATION THERAPY DEVICES MARKET, 2011 
FIGURE 11 COMPACT ADVANCED RADIOTHERAPY SYSTEMS 
FIGURE 12 CYBERKNIFE MARKET, BY VOLUME (NO. OF INSTALLATION UNITS), 2009 – 2016 
FIGURE 13 CYBERKNIFE MARKET ANALYSIS, BY VOLUME & VALUE, 2009 – 2016 
FIGURE 14 GAMMAKNIFE MARKET, BY VOLUME (NO. OF INSTALLATION UNITS), 2009 – 2016 
FIGURE 15 GAMMA KNIFE MARKET ANALYSIS, BY VOLUME & VALUE, 2009 – 2016 
FIGURE 16 VARIOUS STEPS OF THE HELICAL TOMOTHERAPY PROCESS 
FIGURE 17 TOMOTHERAPY MARKET, BY VOLUME (NO. OF INSTALLATION UNITS), 2009 – 2016 
FIGURE 18 TOMOTHERAPY MARKET ANALYSIS, BY VOLUME & VALUE, 2009 – 2016 
FIGURE 19 PROTON THERAPY SYSTEM 
FIGURE 20 EVOLUTION OF ACCELERATORS 
FIGURE 21 MECHANISM IN LINEAR ACCELERATOR SYSTEM 
FIGURE 22 LINAC MARKET ANALYSIS, BY VOLUME & VALUE, 2009 – 2016 
FIGURE 23 INTERNAL RADIOTHERAPY SYSTEM 
FIGURE 24 SEEDS MARKET ANALYSIS, BY VOLUME & VALUE, 2009 – 2016 
FIGURE 25 GLOBAL RADIOTHERAPY MARKET REVENUE, BY APPLICATIONS, 2011 
FIGURE 26 GLOBAL EBRT MARKET SHARE, BY APPLICATIONS, 2011 
FIGURE 27 INTERNAL BEAM RADIOTHERAPY TREATMENT PROCESS 
FIGURE 28 GLOBAL IBRT MARKET SHARE, BY APPLICATIONS, 2011 
FIGURE 29 TECHNOLOGICAL EVOLUTION IN RADIOTHERAPY MARKET 
FIGURE 30 GLOBAL RADIOTHERAPY MARKET REVENUE, BY TECHNOLOGY, 2011 
FIGURE 31 GLOBAL EBRT MARKET REVENUE, BY TECHNOLOGY, 2011 & 2016 ($MILLION) 
FIGURE 32 VARIOUS STEPS IN IGRT MECHANISM 
FIGURE 33 VARIOUS STEPS IN 3-D CRT MECHANISM 
FIGURE 34 ADAPTIVE RADIOTHERAPY TREATMENT CHAIN 
FIGURE 35 EBRT MARKET, BY GEOGRAPHY, 2011 ($MILLION) 
FIGURE 36 NORTH AMERICA: RADIOTHERAPY MARKET SHARE, 2011 & 2016 
FIGURE 37 EUROPE: RADIOTHERAPY MARKET SHARE, 2011 & 2016 
FIGURE 38 ASIA: RADIOTHERAPY MARKET SHARE, 2011 & 2016 
FIGURE 39 ROW INCLUDING JAPAN: RADIOTHERAPY MARKET SHARE, 2011 & 2016 
FIGURE 40 KEY GROWTH STRATEGIES, JANUARY 2009 – MAY 2012

Radiotherapy is the process of treatment of affected tissue through energy emitting particles such as X-rays, gamma rays, electron beams, or protons. There is a broad array of electromagnetic waves depending upon its frequencies and wavelengths. The shorter the wavelength, the higher the destruction capacity of damaged tissues. This short wavelength damages the tissues with ionizing radiation. Radiation generates free radicals and direct ionization of oxygen molecules. These ionized molecules cause different kind of DNA damages such as double strand breakage of DNA strands. This DNA damages lead to cell death.

The radiotherapy industry is under dramatic transformation globally and would see significant changes in the coming years, primarily driven by technological innovation, globalization and rising reimbursement support in the western healthcare systems. Recent developments in radiotherapy devices and technologies have led to the emergence of new fully comprehensive systems, enabling diagnosis, treatment, and follow-up all simultaneously. Compact advanced radiotherapy devices segments of radiotherapy market show tremendous potential and performance in the coming years and represent the fastest market growth.

The global radiotherapy devices market, consisting of devices used in external beam radiation therapy, internal beam radiotherapy and systemic radiation therapy, was valued at $4.4 billion in 2011 and is expected to reach $5.8 billion by 2016, at a CAGR of 5.3% from 20111 to 2016. External beam therapy embraces the highest share (81.5%) of this market. External beam radiotherapy market is primarily driven by electron emitting high energy linear accelerators, followed by compact advanced radiotherapy systems and proton therapy systems.

Compact advanced radiotherapy systems such as CyberKnife, Gamma Knife and TomoTherapy added optimum value to the radiotherapy outcome with a comprehensive system of linear accelerator and high quality imaging system. Currently, 4D IGRT and next generation IMRT and IGRT have grown largely in the radiotherapy market by providing better quality services. Volumetric Modulated Arc Therapy (V-MAT) and Adaptive Radiation Therapy are two significant evolutions among all.

Developed countries such as U.S., Europe have already considered radiotherapy procedure as the gold standard for cancer treatment. A considerable amount of clinical research data on the better clinical outcomes through this new therapy is driving the demand of the novel radiotherapy devices market. The U.S., Europe and Japan have been the pioneer in this medical revolution. Majorly, U.S. and Europe comprise the maximum share of this market but developing countries such as Asian countries and other regions of the world are adopting new policies to welcome this therapeutic procedure in the fight against cancer.

Radiotherapy Devices Market share analysis

Source: Annual Report, SEC Filings, Expert Interviews, MnM Analysis